ALFA Finder| Value | ₹95.00 Cr |
|---|
NSE filing, NSE: COHANCE. Summary written from the filing by ALFA Finder's alert engine.
Cohance Lifesciences Ltd: key numbers
- Share price
- ₹463.50
- Market cap
- ₹17,735 Cr
- Revenue (annual)
- ₹2,269 Cr
- Net profit (annual)
- ₹179.2 Cr
- P/E (TTM)
- 374.4×Sector 43.4×
- Promoter holding
- 57.48%-0.01% QoQ
- FII holding
- 7.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cohance Lifesciences Ltd
All →Cohance Lifesciences Capital Structure Change
Jasti group entities transferred 51,00,000 Cohance shares to Jasub Property Holdings LLP via inter-se block deals. Combined group holding remains 6.36%.
Cohance Lifesciences Business Update
Cohance Lifesciences disclosed that USFDA issued the Establishment Inspection Report for its Pashamylaram facility, classifying the inspection as Voluntary Action Indicated. The inspection is now concluded.
Cohance Lifesciences Management Change
Cohance Lifesciences appointed Kuber Jagdale as Executive Director for 60 months, effective 7 November 2026. He brings over three decades of pharmaceutical manufacturing and operations experience.
Cohance Lifesciences Earnings Call Transcript: Key Takeaways
Q2 revenue rose about 13% QoQ to ₹477 Cr and adjusted EBITDA reached about ₹46 Cr (~10% margin), but both remain below last year. H2 YoY growth is promised without figures, and FY27 specialty chemicals guidance was cut to decline.
Cohance Lifesciences Results Update
Cohance Lifesciences issued a press release on its unaudited Q2 and H1 FY27 results. It reported lower year-on-year revenue and an expected stronger second half.
Cohance Lifesciences Investor Presentation: Key Takeaways
Q2FY27 revenue INR 4,766 Mn, down 14.2% YoY but up 12.9% QoQ. Adjusted EBITDA margin 9.6%, adjusted PAT INR 74 Mn back positive. Strategy centres on One Cohance integration and H2 recovery.
Other merger & restructuring announcements
All →Dabur India Merger & Restructuring
Dabur India disclosed that Atlanta Body and Health Products, a step-down subsidiary, was liquidated and closed effective 10 November 2026. No consideration or financial amount is stated.
Bondada Engineering Merger & Restructuring Worth ₹0.05 Cr
Bondada Engineering incorporated Bondada International FZ-LLC in RAKEZ, UAE, as a wholly owned subsidiary. The subscription amounts to AED 20,000, about Rs.0.05 Crore.
- Value
- ₹0.05 Cr
Deepak Fertilisers & Petrochemicals Corporation Merger & Restructuring Worth ₹0.75 Cr
Deepak Fertilisers incorporated Mahadhan Nutritek Solutions as a step-down wholly owned subsidiary on 26 October 2026. Initial subscription of Rs 0.75 Crore; no business commenced yet.
- Value
- ₹0.75 Cr
Trident Techlabs Merger & Restructuring Worth ₹1.24 Cr
Trident Techlabs incorporated a 99%-owned UAE subsidiary, Techlabs Engineering Consultancy L.L.C., in Abu Dhabi. The company subscribed AED 4.95 lakh, about Rs.1.24 Crore, for 495 shares.
- Value
- ₹1.24 Cr
Olectra Greentech Merger & Restructuring Worth ₹0 Cr
Olectra Greentech agreed to sell its 34% stake in Evey Trans (UJJ) to related party Evey Trans Private Limited for Rs 34,000. Completion is expected by February 2027.
- Value
- ₹0.00 Cr
- Execution
- Completion expected by 2027-02-09
Jubilant Ingrevia Merger & Restructuring
Jubilant Ingrevia updated on a restructuring share subscription and purchase agreement closing in two tranches. First tranche is due by November 2026, second by September 2027.
- Execution
- First tranche by November 2026; second tranche by September 2027